Recently, the source of tau seeds used in the intracranial delivery experiments has caused some debate with regard to which source of tau aggregates (recombinant tau fibrils, or fibrils from patients or transgenic mice in the form of brain extract) may be more relevant to human tauopathies. This evidence concerns the gene MAPT and tauopathy.